The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Open accessAbstract
BACKGROUND: The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity. METHODS: We report findings in 23 patients who presented with thrombosis and thrombocytopenia 6 to 24 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca). On the basis of their clinical and laboratory features, we identify a novel underlying mechanism and address the therapeutic implications. RESULTS: In the absence of previous prothrombotic medical conditions, 22 patients presented with acute thrombocytopenia and thrombosis, primarily cerebral venous thrombosis, and 1 patient presented with isolated thrombocytopenia and a hemorrhagic phenotype. All the patients had low or normal fibrinogen levels and elevated d-dimer levels at presentation. No evidence of thrombophilia or causative precipitants was identified. Testing for antibodies to platelet factor 4 (PF4) was positive in 22 patients (with 1 equivocal result) and negative in 1 patient. On the basis of the pathophysiological features observed in these patients, we recommend that treatment with platelet transfusions be avoided because of the risk of progression in thrombotic symptoms and that the administration of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence of these symptoms. CONCLUSIONS: Vaccination against SARS-CoV-2 remains critical for control of the Covid-19 pandemic. A pathogenic PF4-dependent syndrome, unrelated to the use of heparin therapy, can occur after the administration of the ChAdOx1 nCoV-19 vaccine. Rapid identification of this rare syndrome is important because of the therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Hospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood, E. G., Burton, J., Fort, D., & Seoane, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmsa2011686 · Cited by 1,660
Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., Bellani, G., Bonanomi, E., Cabrini, L., Carlesso, E., Castelli, G., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3539 · Cited by 1,612
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30773-8 · Cited by 633
COVID-19: A review of therapeutic strategies and vaccine candidates
Izda, V., Jeffries, M. A., & Sawalha, A. H. (2021) · Clinical Immunology · doi:10.1016/j.clim.2020.108634 · Cited by 274
Delayed-Onset Heparin-Induced Thrombocytopenia
Rice, L., Attisha, W. K., Drexler, A., & Francis, J. L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00009 · Cited by 265
Warkentin, T. E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1636645 · Cited by 175
A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia
Warkentin, T. E., Makris, M., Jay, R. M., & Kelton, J. G. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.03.012 · Cited by 170
Cited by
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,125
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105290 · Cited by 670
Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis
Pavord, S., Scully, M., Hunt, B. J., Lester, W., Bagot, C., Craven, B., Rampotas, A., Ambler, G., & Makris, M. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109908 · Cited by 587
Self-citationSee, I., Su, J. R., Lale, A., Woo, E. J., Guh, A. Y., Shimabukuro, T. T., Streiff, M. B., Rao, A. K., Wheeler, A. P., Beavers, S. F., et al. (2021) · JAMA · doi:10.1001/jama.2021.7517 · Cited by 532
SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia
Cines, D. B., & Bussel, J. B. (2021) · New England Journal of Medicine · doi:10.1056/nejme2106315 · Cited by 504
New‐onset autoimmune phenomena post‐COVID‐19 vaccination
Chen, Y., Xu, Z., Wang, P., Li, X., Shuai, Z., Ye, D., & Pan, H. (2022) · Immunology · doi:10.1111/imm.13443 · Cited by 502
Pottegård, A., Lund, L. C., Karlstad, Ø., Dahl, J., Andersen, M., Hallas, J., Lidegaard, Ø., Tapia, G., Gulseth, H. L., Ruiz, P. L.-D., et al. (2021) · BMJ · doi:10.1136/bmj.n1114 · Cited by 401
Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., Zaccardi, F., Watkinson, P., Shankar-Hari, M., Doidge, J., et al. (2021) · BMJ · doi:10.1136/bmj.n1931 · Cited by 371
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
Greinacher, A., Selleng, K., Palankar, R., Wesche, J., Handtke, S., Wolff, M., Aurich, K., Lalk, M., Methling, K., Völker, U., et al. (2021) · Blood · doi:10.1182/blood.2021013231 · Cited by 332
Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia
Huynh, A., Kelton, J. G., Arnold, D. M., Daka, M., & Nazy, I. (2021) · Nature · doi:10.1038/s41586-021-03744-4 · Cited by 308
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
Knight, J. S., Branch, D. W., & Ortel, T. L. (2023) · BMJ · doi:10.1136/bmj-2021-069717 · Cited by 265
Fibrin drives thromboinflammation and neuropathology in COVID-19
Ryu, J. K., Yan, Z., Montano, M., Sozmen, E. G., Dixit, K., Suryawanshi, R. K., Matsui, Y., Helmy, E., Kaushal, P., Makanani, S. K., et al. (2024) · Nature · doi:10.1038/s41586-024-07873-4 · Cited by 116
“Notably, we do not believe that this mechanism is related to the rare clotting complications observed with adenovirus based COVID vaccines because the production of anti-PF4 autoantibodies and ensuing drop in platelet counts are triggered by the vector rather than spike 36 .”
Aladdin, Y., Algahtani, H., & Shirah, B. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.105938 · Cited by 48
Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., Duarte‐Salles, T., Fernandez‐Bertolin, S., Aragón, M., Reyes, C., et al. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5419 · Cited by 43
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
“At present, up to fifteen countries (Austria, Bulgaria, Czechia, Denmark, Finland, France, Germany, Iceland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Slovenia and Spain) are using a heterologous vaccination regimen [159].”
ResultUmbrello, M., Brena, N., Vercelli, R., Foa, R. A., Femia, M., Rossi, U., Podda, G. M., Cortellaro, F., & Muttini, S. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.05.021 · Cited by 21
“During the review process of this report, several other papers [2-7] described cases of a new syndrome characterized by thrombocytopenia and deep thrombosis, which developed 5 to 24 days after administration of ChAdOx1 nCoV-19, a recombinant chimpanzee adenoviral-”
Metadata
- Authors
- Scully, M., Singh, D., Lown, R., Poles, A., Solomon, T., Levi, M., Goldblatt, D., Kotoucek, P., Thomas, W., & Lester, W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-06-10
- Volume
- 384
- Issue
- 23
- Pages
- 2202-2211
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3154877986
- Cited by
- 964
- References
- 19
- FWCI
- 188.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.